ResMed Inc. reported an insider stock sale by its Global General Counsel. The Form 4 shows that officer Michael J. Rider sold 50 shares of ResMed common stock on 12/01/2025 at a price of $244.16 per share. After this transaction, he beneficially owned 9,791 shares of ResMed common stock directly.
The filing notes that the sale was made under a pre-arranged Rule 10b5-1 trading plan that was adopted on February 28, 2025, which is designed to allow insiders to sell shares according to a set schedule.
ResMed Inc.'s Chief Financial Officer reports a routine stock sale. On 12/01/2025, the CFO sold 1,000 shares of ResMed common stock at a price of $244.16 per share in an open market transaction. The filing notes that this sale was conducted under a pre-arranged Rule 10b5-1 trading plan that was adopted on February 19, 2025, which is designed to allow insider transactions under preset instructions.
After this transaction, the CFO continues to beneficially own 87,495 ResMed shares, held directly. The filing does not report any derivative securities transactions, indicating that this update relates only to common stock ownership.
An insider of RMD has filed a notice to sell 1,000 shares of common stock through Fidelity Brokerage Services on the NYSE, with an aggregate market value of $244,160. These shares were acquired on 11/11/2022 through restricted stock vesting as compensation from the issuer.
In the past three months, the same seller reported three additional sales: 3,000 shares on 09/02/2025 for gross proceeds of $812,310, 3,000 shares on 10/01/2025 for $823,080, and 3,000 shares on 11/03/2025 for $742,620. The issuer lists 145,966,294 shares of common stock outstanding, providing scale versus these planned and recent insider sales.
ResMed Inc. (RMD) reported an equity compensation grant to its Chairman and CEO on a Form 4. On 11/24/2025, he received options to purchase 33,288 shares of ResMed common stock at an exercise price of $250.52 per share. These options first become exercisable on 11/11/2026 and vest in three equal annual installments starting on that date, aligning his incentives with longer-term company performance. Following this grant, he beneficially owns 466,223 shares of ResMed common stock held directly.
ResMed Inc. (RMD) reported that one of its directors received a grant of 1,331 stock options on ResMed common stock with an exercise price of $250.52 per share. These options become exercisable on the earlier of November 11, 2026, or the date of the first annual meeting of stockholders following the grant date, and expire on November 11, 2032.
After this reported transaction, the director beneficially owns 70,773 shares of ResMed common stock directly, as well as 1,331 stock options directly.
ResMed Inc. director Nicole Mowad-Nassar reported equity transactions involving the company’s stock. As a member of the board of directors, she filed a Form 4 as a single reporting person.
On 11/24/2025, she was granted stock options on 1,331 shares of ResMed common stock at an exercise price of $250.52 per share. These options become exercisable on the earlier of November 11, 2026, or the date of the first annual meeting of stockholders following the grant date. The filing also shows a disposition of 777 shares of ResMed common stock, reflecting routine personal trading activity by a director.
ResMed Inc. insider plans sale of common shares under Rule 144. The notice covers a proposed sale of 2,055 common shares through Fidelity Brokerage Services LLC on the NYSE, with an aggregate market value of $524,025.00. The issuer has 145,966,294 common shares outstanding. The shares derive from restricted stock vesting awards granted as compensation on 11/11/2021 and 11/11/2024.
During the past three months, the same seller, Jan De Witte, sold 487 common shares on 11/11/2025 for gross proceeds of $121,871.75. By signing the notice, the seller represents that he does not know any material adverse information about ResMed’s current or prospective operations that has not been publicly disclosed.
ResMed Inc. (RMD) filed a Form 4 disclosing that its Chief Product Officer acquired 1,848 shares of common stock on 11/20/2025. These shares came from performance-based restricted stock units that were originally granted on November 16, 2022 and were earned when the compensation and leadership development committee certified that the performance targets were met.
After this transaction, the officer beneficially owns 29,028 shares of ResMed common stock in direct ownership. The transaction was reported as an acquisition at a price of $0, reflecting the vesting of equity compensation rather than an open-market purchase.
ResMed Inc. (RMD) reported a director equity grant on a Form 4. On 11/20/2025, a company director acquired 1,073 shares of ResMed common stock through a stock award at a stated price of $0 per share, reflecting a grant of restricted stock units.
After this transaction, the reporting person beneficially owned 5,118 shares of ResMed common stock in direct ownership. The restricted stock units vest in full on the earlier of 11/11/2026 or the annual meeting of stockholders in the year following the grant date, aligning the director’s compensation with shareholder interests over that period.
ResMed Inc. (RMD) reported an insider equity award for director Nicole Mowad-Nassar on a Form 4. On 11/20/2025, she received 536 shares of ResMed common stock as a grant of restricted stock units at a stated price of $0 per share, reflecting a stock-based award rather than an open-market purchase. Following this transaction, she beneficially owned 777 shares directly.
The filing notes that these restricted stock units vest in full on the earlier of 11/11/2026 or the annual meeting of stockholders held in the year following the grant date. This is a routine director compensation transaction and does not involve any derivative securities.